Evaluation of sitagliptin therapy on the levels of fibroblast growth factor-19 (FGF19) in patients with Type 2 diabetes
Turkish Journal of Internal Medicine · 2022
DOI: 10.46310/tjim.1070223 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Internal Medicine, 2022. Verfasst von Özen ÖZ GÜL und 1 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
The specific association between sitagliptin and Fibroblast Growth Factor-19 (FGF19) is yet to be clarified. In this study, we aimed to investigate the effect of sitagliptin therapy on the levels of FDF19 in patients with type 2 diabetes mellitus (T2DM).
Methods
A total of 35 patients newly diagnosed type 2 diabetes, and who had not received antidiabetic treatment before were included in this study. Sitagliptin therapy was administered as 100 mg/day. Patients’ demographic, anthropometric features, glycaemic variables, lipid profiles and FGF19 values were evaluated at the baseline and at the 3rd month of the treatment and the obtained data were compared.
Results
The mean age of the patients was 53.34 ± 8.09 years. The mean weight, body mass index (BMI), hip circumference, postprandial blood glucose and glycosylated haemoglobin A1c (HbA1c) values were statistically significantly lower at the 3rd month of the treatment compared to the baseline values (for all, p
Zitieren
APA
GÜL, Ö. Ö., & CANDER, S. (2022). Evaluation of sitagliptin therapy on the levels of fibroblast growth factor-19 (FGF19) in patients with Type 2 diabetes. Turkish Journal of Internal Medicine. https://doi.org/10.46310/tjim.1070223
Vancouver
GÜL ÖÖ, CANDER S. Evaluation of sitagliptin therapy on the levels of fibroblast growth factor-19 (FGF19) in patients with Type 2 diabetes. Turkish Journal of Internal Medicine. 2022. doi:10.46310/tjim.1070223
BibTeX
@article{GL2022,
author = {GÜL, Özen ÖZ and CANDER, Soner},
title = {Evaluation of sitagliptin therapy on the levels of fibroblast growth factor-19 (FGF19) in patients with Type 2 diabetes},
journal = {Turkish Journal of Internal Medicine},
year = {2022},
doi = {10.46310/tjim.1070223}
}
EUVIMED